Literature DB >> 15523076

Risks and benefits of phase 1 clinical trials evaluating new anticancer agents: a case for more innovation.

Eric X Chen, Ian F Tannock.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15523076     DOI： 10.1001/jama.292.17.2150

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  5 in total

1.  Lost in migration.

Authors:  George S Mack; Andrew Marshall
Journal:  Nat Biotechnol       Date:  2010-03       Impact factor: 54.908

2.  American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment.

Authors:  Jeffrey S Weber; Laura A Levit; Peter C Adamson; Suanna Bruinooge; Howard A Burris; Michael A Carducci; Adam P Dicker; Mithat Gönen; Stephen M Keefe; Michael A Postow; Michael A Thompson; David M Waterhouse; Susan L Weiner; Lynn M Schuchter
Journal:  J Clin Oncol       Date:  2014-12-15       Impact factor: 44.544

3.  Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse.

Authors:  Rajul K Jain; J Jack Lee; David Hong; Maurie Markman; Jing Gong; Aung Naing; Jennifer Wheler; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

4.  First-in-human trial participants: not a vulnerable population, but vulnerable nonetheless.

Authors:  Rebecca Dresser
Journal:  J Law Med Ethics       Date:  2009       Impact factor: 1.718

5.  Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in Oncology.

Authors:  Joeri A J Douma; Laurien M Buffart; Ramy Sedhom; Mariette Labots; Willemien C Menke-van der Houven van Oordt; Mikkjal Skardhamar; Anthony De Felice; Esther Lee; Divya Dharmaraj; Nilofer S Azad; Michael A Carducci; Henk M W Verheul
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.